ADAURA Study Demonstrates Promising Efficacy for Osimertinib in EGFR-Mutant NSCLC
Masahiro Tsuboi, MD, discusses the key takeaways from the findings for osimertinib in patients with early-stage EGFR-mutant non–small cell lung cancer following a complete tumor resection in the phase 3 ADAURA clinical trial.
Masahiro Tsuboi, MD, a surgeon at Japan’s National Cancer Center Hospital East, discusses the key takeaways from the findings for osimertinib (Tagrisso) in patients with early-stage EGFR-mutant non–small cell lung cancer (NSCLC) following a complete tumor resection in the phase 3 ADAURA clinical trial (NCT02511106), which were presented during the 2020 European Society for Medical Oncology (ESMO) Virtual Congress.
According to these results, adjuvant osimertinib demonstrated a clinically meaningful improvement in central nervous system disease-free survival compared with placebo. Treatment with osimertinib following complete tumor resection reduced the risk for central nervous system death or progression by 82%. Tsuboi says low rates of recurrence, particularly in the brain, were also observed in the study.
Based on the findings from this study, adjuvant osimertinib would be an effective and practice-changing treatment approach for patients with early-stage EGFR-mutant NSCLC.
